1
Liver cirrhosis was the main risk factor for HCC development in Brazil.
2
One patient with preexisting cirrhosis required liver transplantation; all others resolved clinically.
3
Very little information is available on body composition in patients with cirrhosis.
4
Conclusions: PPI therapy is associated with SBP in patients with advanced cirrhosis.
5
Conclusion: Terlipressin decreases hepatic and renal arterial resistance in patients with cirrhosis.